Botulinum neurotoxins: Mechanism of action

Toxicon

Volumn 67, Issue , 2013, Pages 87-93

  Tighe, Ann P ^a   Schiavo, Giampietro ^b,c  

^a Lincoln's Inn Fields Laboratories ^*  (United States)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Botulinum neurotoxin; Mechanism of action; Neuromuscular junction; SNAP 25; SNARE complex; Synaptic transmission

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; GANGLIOSIDE; MULTIPROTEIN COMPLEX; NEUTRALIZING ANTIBODY; POLYSIALOGANGLIOSIDE; SNARE PROTEIN; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIBODY PRODUCTION; ANTICHOLINERGIC SYNDROME; AUTONOMIC DYSFUNCTION; BINDING AFFINITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; CERVICAL DYSTONIA; CONSTIPATION; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STABILITY; DRUG TREATMENT FAILURE; HEART RATE; HEMIFACIAL SPASM; HUMAN; HYPERSALIVATION; HYPOSALIVATION; IMMUNOGENICITY; INHIBITION KINETICS; MOLECULAR WEIGHT; NERVE CELL EXCITABILITY; NERVE ENDING; NERVE REGENERATION; NERVE SPROUTING; NEUROMUSCULAR SYNAPSE; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SWEAT GLAND DISEASE; SYNAPTIC MEMBRANE; SYNAPTIC TRANSMISSION; TOXIN ANALYSIS; TOXIN STRUCTURE; TOXIN SYNTHESIS; TREATMENT DURATION; URINARY TRACT DISEASE;

EID: 84877704954     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2012.11.011     Document Type: Review

References (51)

1. Arndt J.W., Jacobson M.J., Abola E.E., Forsyth C.M., Tepp W.H., Marks J.D., Johnson E.A., Stevens R.C. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 2006, 362:733-742.
2. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
3. Bach-Rojecky L., Salkovic-Petrisic M., Lackovic Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur. J. Pharmacol. 2010, 633:10-14.
4. Bakheit A.M. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr. Drug Saf. 2006, 1:271-279.
5. Bercsenyi K., Giribaldi F., Schiavo G. The elusive compass of clostridial neurotoxins: deciding when and where to go. Curr. Top. Microbiol. Immunol. 2013, 364:91-113. 10.1007/978-3-642-33570-9_5.
6. Caleo M., Schiavo G. Central effects of tetanus and botulinum neurotoxins. Toxicon 2009, 54:593-599.
7. Collins M.D., East A.K. Phylogeny and taxonomy of the food-borne pathogen Clostridium botulinum and its neurotoxins. J. Appl. Microbiol. 1998, 84:5-17.
8. Darios F., Niranjan D., Ferrari E., Zhang F., Soloviev M., Rummel A., Bigalke H., Suckling J., Ushkaryov Y., Naumenko N., Shakirzyanova A., Giniatullin R., Maywood E., Hastings M., Binz T., Davletov B. SNARE tagging allows stepwise assembly of a multimodular medicinal toxin. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18197-18201.
9. de Paiva A., Meunier F.A., Molgo J., Aoki K.R., Dolly J.O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3200-3205.
10. Dolly J.O., O'Connell M.A. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr. Opin. Pharmacol. 2012, 12:100-108.
11. Dressler D., Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil. Rehabil. 2007, 29:1761-1768.
12. Dupuy B., Matamouros S. Regulation of toxin and bacteriocin synthesis in Clostridium species by a new subgroup of RNA polymerase sigma-factors. Res. Microbiol. 2006, 157:201-205.
13. Eisele K.H., Fink K., Vey M., Taylor H.V. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011, 57:555-565.
14. Frevert J., Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. Biologics 2010, 4:325-332.
15. Goschel H., Wohlfarth K., Frevert J., Dengler R., Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp. Neurol. 1997, 147:96-102.
16. Gu S., Rumpel S., Zhou J., Strotmeier J., Bigalke H., Perry K., Shoemaker C.B., Rummel A., Jin R. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 2012, 335:977-981.
17. Harrison A.R., Berbos Z., Zaldivar R.A., Anderson B.C., Semmer M., Lee M.S., McLoon L.K. Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle. Invest. Ophthalmol. Vis. Sci. 2011, 52:982-986.
18. Hill K.K., Smith T.J., Helma C.H., Ticknor L.O., Foley B.T., Svensson R.T., Brown J.L., Johnson E.A., Smith L.A., Okinaka R.T., Jackson P.J., Marks J.D. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J. Bacteriol. 2007, 189:818-832.
19. Hill K.K., Xie G., Foley B.T., Smith T.J., Munk A.C., Bruce D., Smith L.A., Brettin T.S., Detter J.C. Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains. BMC Biol. 2009, 7:66.
20. Jankovic J., Vuong K.D., Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60:1186-1188.
21. Karalewitz A.P., Kroken A.R., Fu Z., Baldwin M.R., Kim J.J., Barbieri J.T. Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 2010, 49:8117-8126.
22. Kumaran D., Eswaramoorthy S., Furey W., Navaza J., Sax M., Swaminathan S. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 2009, 386:233-245.
23. Lacy D.B., Stevens R.C. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 1999, 291:1091-1104.
24. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5:898-902.
25. Lalli G., Schiavo G. Analysis of retrograde transport in motor neurons reveals common endocytic carriers for tetanus toxin and neurotrophin receptor p75NTR. J. Cell. Biol. 2002, 156:233-239.
26. Lawrence G.W., Ovsepian S.V., Wang J., Aoki K.R., Dolly J.O. Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochem. J. 2012, 441:443-452.
27. Lee J.C., Yokota K., Arimitsu H., Hwang H.J., Sakaguchi Y., Cui J., Takeshi K., Watanabe T., Ohyama T., Oguma K. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 2005, 151:3739-3747.
28. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 2010, 79:591-617.
29. Muraro L., Tosatto S., Motterlini L., Rossetto O., Montecucco C. The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem. Biophys. Res. Commun. 2009, 380:76-80.
30. Peck M.W. Biology and genomic analysis of Clostridium botulinum. Adv. Microb. Physiol. 2009, 55:183-265.
31. Peng L., Tepp W.H., Johnson E.A., Dong M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 2011, 7:e1002008.
32. Poulain B. How do the Botulinum Neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J. 2008, 1:14-87.
33. Restani L., Antonucci F., Gianfranceschi L., Rossi C., Rossetto O., Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J. Neurosci. 2011, 31:15650-15659.
34. Restani, L., Giribaldi, F., Manich, M., Bercsenyi, K., Menendez, G., Rossetto, O., Caleo, M., Schiavo, G. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog., in press.
35. Rossetto O., Montecucco C. Presynaptic neurotoxins with enzymatic activities. Handb. Exp. Pharmacol. 2008, 129-170.
36. Rummel A., Karnath T., Henke T., Bigalke H., Binz T. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 2004, 279:30865-30870.
37. Schiavo G. Dangerous liaisons on neurons. Nature 2006, 444:1019-1020.
38. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
39. Sebaihia M., Peck M.W., Minton N.P., Thomson N.R., Holden M.T., Mitchell W.J., Carter A.T., Bentley S.D., Mason D.R., Crossman L., Paul C.J., Ivens A., Wells-Bennik M.H., Davis I.J., Cerdeno-Tarraga A.M., Churcher C., Quail M.A., Chillingworth T., Feltwell T., Fraser A., Goodhead I., Hance Z., Jagels K., Larke N., Maddison M., Moule S., Mungall K., Norbertczak H., Rabbinowitsch E., Sanders M., Simmonds M., White B., Whithead S., Parkhill J. Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes. Genome Res. 2007, 17:1082-1092.
40. Sharma S.K., Singh B.R. Immunological properties of Hn-33 purified from type A Clostridium botulinum. J. Nat. Toxins 2000, 9:357-362.
41. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44:167-193.
42. Strotmeier J., Lee K., Volker A.K., Mahrhold S., Zong Y., Zeiser J., Zhou J., Pich A., Bigalke H., Binz T., Rummel A., Jin R. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem. J. 2010, 431:207-216.
43. Sudhof T.C., Rothman J.E. Membrane fusion: grappling with SNARE and SM proteins. Science 2009, 323:474-477.
44. Sugawara Y., Matsumura T., Takegahara Y., Jin Y., Tsukasaki Y., Takeichi M., Fujinaga Y. Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. J. Cell Biol. 2010, 189:691-700.
45. Swaminathan S., Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7:693-699.
46. Tam S.L., Gordon T. Mechanisms controlling axonal sprouting at the neuromuscular junction. J. Neurocytol. 2003, 32:961-974.
47. Tintner R., Gross R., Winzer U.F., Smalky K.A., Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005, 65:765-767.
48. Tsai Y.C., Maditz R., Kuo C.L., Fishman P.S., Shoemaker C.B., Oyler G.A., Weissman A.M. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:16554-16559.
49. Tsukamoto K., Kohda T., Mukamoto M., Takeuchi K., Ihara H., Saito M., Kozaki S. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J. Biol. Chem. 2005, 280:35164-35171.
50. Wang J., Zurawski T.H., Meng J., Lawrence G., Olango W.M., Finn D.P., Wheeler L., Dolly J.O. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J. Biol. Chem. 2011, 286:6375-6385.
51. Zhang Y., Buchko G.W., Qin L., Robinson H., Varnum S.M. Structural analysis of the receptor binding domain of botulinum neurotoxin serotype D. Biochem. Biophys. Res. Commun. 2010, 401:498-503.